Related Experiment Videos
Adjunctive pharmacologic therapy for acute myocardial infarction
1Division of Cardiology, University of Florida, College of Medicine, Gainesville 32610.
Insights
Early reperfusion therapy improves survival for acute myocardial infarction (AMI). Adjunctive pharmacologic therapies, including aspirin and heparin, further reduce mortality and morbidity in AMI patients.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Acute myocardial infarction (AMI) treatment relies on early reperfusion therapy.
- Intravenous thrombolysis is standard but not suitable for all patients.
- Persistent or reoccurring artery occlusion affects 25-30% of treated patients.
Purpose of the Study:
- To evaluate the role of adjunctive pharmacologic therapy in improving outcomes for AMI patients.
- To identify effective combinations of medications used alongside reperfusion therapy.
Main Methods:
- Review of emerging data on adjunctive pharmacologic agents.
- Analysis of studies investigating combinations of aspirin, heparin, beta-blockers, and ACE inhibitors.
Main Results:
- Adjunctive therapies aim to address limitations of reperfusion alone.
- Certain combinations of medications show promise in reducing morbidity and mortality.
- A recommended regimen includes aspirin, heparin, beta-blockers, and ACE inhibitors.
Conclusions:
- Adjunctive pharmacologic therapy is crucial for optimizing AMI treatment.
- Combining specific agents with reperfusion therapy offers additional survival benefits.
- Standard adjunctive therapy should include aspirin, heparin, beta-blockers, and ACE inhibitors.
Abstract:
Early reperfusion therapy, usually in the form of intravenous thrombolysis, is accepted as the standard therapy for patients with acute myocardial infarction. While thrombolytic therapy has been conclusively shown to reduce mortality, a large percentage of patients are not candidates for this therapy and, even in those who are candidates, as many as 25-30% have persistent occlusion or reocclusion of the infarct-related artery. Adjunctive pharmacologic therapy evolved in an attempt to address these issues and is given in addition to reperfusion therapy. Adjunctive therapy includes administration of one or more of the following: aspirin, heparin, beta-adrenergic blockers, nitroglycerin, heart-rate slowing calcium antagonists, and angiotensin-converting enzyme inhibitors. Data are emerging that indicate that some of these agents provide additional reduction in morbidity and mortality when used as adjunctive strategies. Currently, a recommended combination includes, at minimum, soluble aspirin, intravenous heparin, an intravenous beta-blocking agent, and oral angiotensin-converting enzyme inhibitor.